Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study
Chaojing Wen, Yixuan Wang, Haoyue Tian, Yu Lei, Zhiyi Wang, Dachuan Cai, Zhi Zhou, Xiaofeng Shi · 2024
Read Clinical cure induced by pegylated interferon α-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study by Chaojing Wen, Yixuan Wang, Haoyue Tian, Yu Lei, Zhiyi Wang, Dachuan Cai, Zhi Zhou, Xiaofeng Shi (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10824921.txt.
Description
Chaojing Wen and co-authors reported this cohort study on a shot-based treatment for long-term hepatitis B. Some patients carry the virus quietly, while others have already taken daily pills for it. The shot, a pegylated interferon, can sometimes clear a key virus marker from the blood, which counts as a clinical cure. The head record dates the paper to 2023, though the catalog lists 2024.
The study enrolled 270 patients split into four groups. Two groups got the shot, alone or added to pills, and two control groups got pills alone or no treatment. At 48 weeks, about 66 percent of the quiet-carrier group cleared the marker, against about 53 percent in the add-on group. The paper weighs whether both patient types gain alike from the shot.
Catalog record
| CREATOR | Chaojing Wen, Yixuan Wang, Haoyue Tian, Yu Lei, Zhiyi Wang, Dachuan Cai, Zhi Zhou, Xiaofeng Shi |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |